Birth Prevalence of Fatty Acid β-Oxidation Disorders in Iberia
Authors
Affiliations
Mitochondrial fatty acid β-oxidation disorders (FAOD) are main targets for newborn screening (NBS) programs, which are excellent data sources for accurate estimations of disease birth prevalence. Epidemiological data is of key importance for the understanding of the natural history of the disorders as well as to define more effective public health strategies. In order to estimate FAOD birth prevalence in Iberia, the authors collected data from six NBS programs from Portugal and Spain, encompassing the screening of more than 1.6 million newborns by tandem mass spectrometry (MS/MS), and compared it with available data from other populations. The participating NBS programs are responsible for the screening of about 46% of all Iberian newborns. Data reveals that Iberia has one of the highest FAOD prevalence in Europe (1:7,914) and that Portugal has the highest birth prevalence of FAOD reported so far (1:6,351), strongly influenced by the high prevalence of medium-chain acyl-CoA dehydrogenase deficiency (MCADD; 1:8,380), one of the highest ever reported. This is justified by the fact that more than 90% of Portuguese MCADD patients are of Gypsy origin, a community characterized by a high degree of consanguinity. From the comparative analysis of various populations with comparable data other differences emerge, which points to the existence of significant variations in FAOD prevalences among different populations, but without any clear European variation pattern. Considering that FAOD are one of the justifications for MS/MS NBS, the now estimated birth prevalences stress the need to screen all Iberian newborns for this group of inherited metabolic disorders.
Portuguese Neonatal Screening Program: A Cohort Study of 18 Years Using MS/MS.
Goncalves M, Marcao A, Sousa C, Nogueira C, Fonseca H, Rocha H Int J Neonatal Screen. 2024; 10(1).
PMID: 38535129 PMC: 10971468. DOI: 10.3390/ijns10010025.
Medium-chain Acyl-COA dehydrogenase deficiency: Pathogenesis, diagnosis, and treatment.
Mason E, Hindmarch C, Dunham-Snary K Endocrinol Diabetes Metab. 2022; 6(1):e385.
PMID: 36300606 PMC: 9836253. DOI: 10.1002/edm2.385.
Acylcarnitines: Can They Be Biomarkers of Diabetic Nephropathy?.
Mu X, Yang M, Ling P, Wu A, Zhou H, Jiang J Diabetes Metab Syndr Obes. 2022; 15:247-256.
PMID: 35125878 PMC: 8811266. DOI: 10.2147/DMSO.S350233.
Yang C, Shi C, Zhou C, Wan Q, Zhou Y, Chen X Zhejiang Da Xue Xue Bao Yi Xue Ban. 2021; 50(4):472-480.
PMID: 34704412 PMC: 8714482. DOI: 10.3724/zdxbyxb-2021-0259.
Admixture Has Shaped Romani Genetic Diversity in Clinically Relevant Variants.
Font-Porterias N, Gimenez A, Carballo-Mesa A, Calafell F, Comas D Front Genet. 2021; 12:683880.
PMID: 34220960 PMC: 8244592. DOI: 10.3389/fgene.2021.683880.